Skip to Main Content

Paper Details

RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition.
J Clin Invest
2
2023
-, IL-3, IL-3 receptor, JAK, RUNX1, RUNX1-KO, RUNX1-deficient cells, RUNX1-mutant, RUNX1-mutant leukemias, STAT, blood cancers, hematopoietic and leukemic cells, human, leukemias, leukemic, patient, primary human hematopoietic cells, stem cell, transcription factor RUNX1
Author NameAffiliation
Yusuke NakauchiInstitute for Stem Cell Biology and Regenerative Medicine.
Yusuke NakauchiCancer Institute.
Yusuke NakauchiStanford University School of Medicine
Thomas K??hnkeInstitute for Stem Cell Biology and Regenerative Medicine.
Thomas K??hnkeCancer Institute.
Thomas K??hnkeStanford University School of Medicine
Purvesh KhatriInstitute for Immunity
Purvesh KhatriCenter for Biomedical Informatics Research, Stanford University
Purvesh KhatriInstitute for Immunity
Purvesh KhatriCenter for Biomedical Informatics Research, Stanford University
Ravindra MajetiInstitute for Stem Cell Biology and Regenerative Medicine.
Ravindra MajetiCancer Institute.
Ravindra MajetiStanford University School of Medicine
  • 1 - 13

Datasets

Release 1.2